Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
7Customers
2Debt Items
7Related Chains
Source-Backed Evidence Depth
Arcutis Biotherapeutics, Inc. (ARQT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
1Distinct source URLs
4High confidence
0.738Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Arcutis Biotherapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
THIRD-PARTIES
THIRD-PARTIES
90%
We rely on third parties to conduct our nonclinical studies and clinical trials, as well as for the manufacturing and supply of our product candidates and for the commercial supply of our products.
Reciprocal relationship from SLRC graph: subsidiary NEFPASS LLC and $64.9 million was used to purchase certain leases and loans held by SLR Equipment through NEFPASS LLC. On January 31, 2024, SLR Equ…
n increase in sales and marketing expenses of $5.9 million and an increase in compensation and employee benefit related expenses of $4.4 million. These increases were primarily due to our continued c…
Reciprocal relationship from SLRC graph: Reciprocal relationship from ARQT graph: Reciprocal relationship from SLRC graph: Reciprocal relationship from ARQT graph: Reciprocal relationship from SLRC g…
ARCUTIS-CANADA-INC
ARCUTIS-CANADA-INC
62%
n increase in sales and marketing expenses of $5.9 million and an increase in compensation and employee benefit related expenses of $4.4 million. These increases were primarily due to our continued c…
COMPANY-LLC
COMPANY-LLC
62%
mary events of default that entitle the lenders to cause any indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against the Company and the collater…
HANGZHOU-ZHONGMEI-HUADONG-PHARMACEUTICAL-CO-LTD
HANGZHOU-ZHONGMEI-HUADONG-PHARMACEUTICAL-CO-LTD
62%
ble was immaterial. The Company has made an accounting policy election not to recognize an allowance for credit losses for accrued interest receivables on available-for-sale securities and to write o…
HUADONG-MEDICINE-CO-LTD
HUADONG-MEDICINE-CO-LTD
62%
ble was immaterial. The Company has made an accounting policy election not to recognize an allowance for credit losses for accrued interest receivables on available-for-sale securities and to write o…
SATO-PHARMACEUTICAL-CO-LTD
SATO-PHARMACEUTICAL-CO-LTD
62%
ble was immaterial. The Company has made an accounting policy election not to recognize an allowance for credit losses for accrued interest receivables on available-for-sale securities and to write o…
Arcutis Biotherapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ARQT-DEBT
Debt stack $108.9M
90%
Market cache reports total debt of $108.9M.
ARQT-DEBT-7854
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Arcutis Biotherapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Arcutis Biotherapeutics, Inc..
Arcutis Biotherapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ARQT-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 272 tracked holders.
Arcutis Biotherapeutics, Inc. Extended Supply Chain Network
